Valuation: Zai Lab Limited

Market Cap 2.62B 44.93B 2.27B 2.12B 1.94B 3.65B 249B 3.71B 24.83B 9.75B 125B 9.84B 9.62B 413B P/E 2026 *
-10.8x
P/E 2027 * -12.1x
Enterprise Value 2.22B 38.15B 1.92B 1.8B 1.65B 3.1B 212B 3.15B 21.08B 8.27B 106B 8.35B 8.17B 351B EV / Sales 2026 *
5.27x
EV / Sales 2027 * 3.86x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
3 years 270.64
Extreme 270.64
810
5 years 270.64
Extreme 270.64
2,446.85
10 years 270.64
Extreme 270.64
3,693.35
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
+43.36%-.--% - - 2.62B
+1.59%+2.85%+40.11%+1.24% 78.32B
-0.84%+0.09%+20.92%+179.15% 49.18B
+2.77%+4.78%-1.65%+27.62% 51.1B
-0.13%+7.42%-50.22%-49.58% 44.71B
+0.80%+2.46%+62.77%-23.33% 30.72B
+1.84%+0.87%+54.17%+85.73% 24.44B
+9.86%+7.94%+122.36%-41.53% 23.62B
+4.29%+9.40%+3.77%+226.51% 21.05B
+1.66%-3.70%+65.40%+123.91% 16.61B
Average +6.52%+4.08%+35.29%+58.86% 37.75B
Weighted average by Cap. +2.20%+4.29%+26.93%+45.10%

Financials

2026 *2027 *
Net sales 422M 7.24B 365M 341M 313M 588M 40.18B 598M 4B 1.57B 20.14B 1.59B 1.55B 66.57B 581M 9.96B 502M 469M 430M 809M 55.25B 822M 5.5B 2.16B 27.69B 2.18B 2.13B 91.56B
Net income -226M -3.87B -195M -182M -167M -314M -21.47B -319M -2.14B -839M -10.76B -847M -829M -35.58B -162M -2.78B -140M -131M -120M -226M -15.41B -229M -1.53B -602M -7.72B -608M -595M -25.54B
Net Debt -396M -6.78B -342M -320M -293M -551M -37.64B -560M -3.75B -1.47B -18.87B -1.49B -1.45B -62.38B -381M -6.53B -329M -308M -282M -531M -36.24B -539M -3.61B -1.42B -18.17B -1.43B -1.4B -60.06B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
23.32USD
Average target price
33.52USD
Spread / Average Target
+43.72%

Quarterly revenue - Rate of surprise